GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
GUIDED THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.16−0.03 (-15.79%)
Close on Oct 19, 2026
- Market cap
- $15.45M
- P/E (TTM)
- –
- Dividend yield
- –
GUIDED THERAPEUTICS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Major Part Components | $100.00K | – | – | – | – | – | – | – | – | 98.0% | – |
| Disposables | $2.00K | $0 | $0 | $0 | $2.00K | $24.00K | $26.00K | $34.00K | $32.00K | 2.0% | 0.0% |
| Devices | $0 | $17.00K | $17.00K | $17.00K | $17.00K | $17.00K | $17.00K | $17.00K | $17.00K | 0.0% | -100.0% |
| Warranty | $0 | $0 | $0 | $1.00K | $2.00K | $5.00K | $5.00K | $8.00K | $7.00K | 0.0% | -100.0% |
| Other | – | – | – | – | – | $16.00K | $15.00K | – | $1.00K | – | – |
By region
| Revenue | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia | $102.00K | $93.00K | $17.00K | $19.00K | $22.00K | $55.00K | $54.00K | $52.00K | $49.00K | 100.0% | +363.6% |
| Europe | $0 | $0 | $0 | – | $14.00K | – | – | – | – | 0.0% | -100.0% |
| North America | – | – | – | – | – | $0 | $0 | $0 | $0 | – | – |
| South America | – | – | – | – | – | $0 | $0 | $0 | $0 | – | – |
| Africa | – | – | – | – | $0 | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Guided Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.